New hope for lung cancer patients who stopped responding to current drug
NCT ID NCT07199010
First seen Oct 31, 2025 · Last updated Jun 05, 2026 · Updated 35 times
Summary
This study observes 50 adults with advanced ROS1-positive non-small cell lung cancer whose disease worsened after treatment with entrectinib. Researchers will track how well taletrectinib works in real-world settings, including tumor shrinkage and safety. The goal is to understand if this next-generation drug can control the cancer when the first targeted therapy fails.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital (The East Hospital Affiliated to Tongji University)
Shanghai, Shanghai Municipality, 200120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.